About A-005

A-005 is the first allosteric tyrosine kinase 2 (TYK2) inhibitor with demonstrated ability to cross the human blood-brain barrier, enabling targeted treatment within the CNS and periphery. Designed for maximal TYK2 inhibition, A-005 holds potential as a first-in-class CNS penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases such as multiple sclerosis (MS), Alzheimer’s disease, and Parkinson’s disease.

Promising Data

In a Phase 1 clinical trial, A-005 was well tolerated with no serious adverse events and achieved maximal TYK2 inhibition across a broad dose range. Data also show that A-005 effectively blocks TYK2 signaling in immune and CNS resident cells, targeting pro-inflammatory pathways linked to neuroinflammatory diseases.

Based on these data, we plan to initiate a Phase 2 clinical trial in patients with MS in the first half of 2026.